Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease

Daniela Galimberti, Chiara Fenoglio, Carlo Lovati, Eliana Venturelli, Ilaria Guidi, Barbara Corrà, Diego Scalabrini, Francesca Clerici, Claudio Mariani, Nereo Bresolin, Elio Scarpini

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Upregulation of a number of chemokines, including monocyte chemotactic protein-1 (MCP-1), is associated with Alzheimer's disease (AD) pathological changes. Emerging evidence suggests that inflammatory events precede the clinical development of AD, as cytokine disregulation has been observed also in patients with mild cognitive impairment (MCI). MCP-1 levels were evaluated in serum samples from 48 subjects with MCI, 94 AD patients and 24 age-matched controls. Significantly increased MCP-1 levels were found in MCI and mild AD, but not in severe AD patients as compared with controls. mRNA levels in peripheral blood mononuclear cells (PBMC), evaluated by quantitative RT-PCR analysis, paralleled serum MCP-1 levels. Moreover, a progressive MCP-1 decrease was observed over a 1-year follow up in a subgroup of MCI subjects converted to AD. MCP-1 upregulation is likely to be a very early event in AD pathogenesis, by far preceding the clinical onset of the disease. Nevertheless, as MCP-1 is likely to play a role in several pathologies with an inflammatory component, a possible usfulness as an early AD biomarker would be possible only in combination with other molecules.

Original languageEnglish
Pages (from-to)1763-1768
Number of pages6
JournalNeurobiology of Aging
Volume27
Issue number12
DOIs
Publication statusPublished - Dec 2006

Fingerprint

Chemokine CCL2
Blood Proteins
Alzheimer Disease
Up-Regulation
Cognitive Dysfunction
Chemokines
Blood Cells
Biomarkers
Pathology
Cytokines
Polymerase Chain Reaction
Messenger RNA
Serum

Keywords

  • Alzheimer's disease (AD)
  • Biomarker
  • Mild cognitive impairment (MCI)
  • Monocyte chemoattractant protein-1 (MCP-1)

ASJC Scopus subject areas

  • Clinical Neurology
  • Biological Psychiatry
  • Developmental Neuroscience
  • Neurology
  • Psychology(all)

Cite this

Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. / Galimberti, Daniela; Fenoglio, Chiara; Lovati, Carlo; Venturelli, Eliana; Guidi, Ilaria; Corrà, Barbara; Scalabrini, Diego; Clerici, Francesca; Mariani, Claudio; Bresolin, Nereo; Scarpini, Elio.

In: Neurobiology of Aging, Vol. 27, No. 12, 12.2006, p. 1763-1768.

Research output: Contribution to journalArticle

Galimberti, Daniela ; Fenoglio, Chiara ; Lovati, Carlo ; Venturelli, Eliana ; Guidi, Ilaria ; Corrà, Barbara ; Scalabrini, Diego ; Clerici, Francesca ; Mariani, Claudio ; Bresolin, Nereo ; Scarpini, Elio. / Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. In: Neurobiology of Aging. 2006 ; Vol. 27, No. 12. pp. 1763-1768.
@article{205e75b659c4446a9442340786eeb043,
title = "Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease",
abstract = "Upregulation of a number of chemokines, including monocyte chemotactic protein-1 (MCP-1), is associated with Alzheimer's disease (AD) pathological changes. Emerging evidence suggests that inflammatory events precede the clinical development of AD, as cytokine disregulation has been observed also in patients with mild cognitive impairment (MCI). MCP-1 levels were evaluated in serum samples from 48 subjects with MCI, 94 AD patients and 24 age-matched controls. Significantly increased MCP-1 levels were found in MCI and mild AD, but not in severe AD patients as compared with controls. mRNA levels in peripheral blood mononuclear cells (PBMC), evaluated by quantitative RT-PCR analysis, paralleled serum MCP-1 levels. Moreover, a progressive MCP-1 decrease was observed over a 1-year follow up in a subgroup of MCI subjects converted to AD. MCP-1 upregulation is likely to be a very early event in AD pathogenesis, by far preceding the clinical onset of the disease. Nevertheless, as MCP-1 is likely to play a role in several pathologies with an inflammatory component, a possible usfulness as an early AD biomarker would be possible only in combination with other molecules.",
keywords = "Alzheimer's disease (AD), Biomarker, Mild cognitive impairment (MCI), Monocyte chemoattractant protein-1 (MCP-1)",
author = "Daniela Galimberti and Chiara Fenoglio and Carlo Lovati and Eliana Venturelli and Ilaria Guidi and Barbara Corr{\`a} and Diego Scalabrini and Francesca Clerici and Claudio Mariani and Nereo Bresolin and Elio Scarpini",
year = "2006",
month = "12",
doi = "10.1016/j.neurobiolaging.2005.10.007",
language = "English",
volume = "27",
pages = "1763--1768",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease

AU - Galimberti, Daniela

AU - Fenoglio, Chiara

AU - Lovati, Carlo

AU - Venturelli, Eliana

AU - Guidi, Ilaria

AU - Corrà, Barbara

AU - Scalabrini, Diego

AU - Clerici, Francesca

AU - Mariani, Claudio

AU - Bresolin, Nereo

AU - Scarpini, Elio

PY - 2006/12

Y1 - 2006/12

N2 - Upregulation of a number of chemokines, including monocyte chemotactic protein-1 (MCP-1), is associated with Alzheimer's disease (AD) pathological changes. Emerging evidence suggests that inflammatory events precede the clinical development of AD, as cytokine disregulation has been observed also in patients with mild cognitive impairment (MCI). MCP-1 levels were evaluated in serum samples from 48 subjects with MCI, 94 AD patients and 24 age-matched controls. Significantly increased MCP-1 levels were found in MCI and mild AD, but not in severe AD patients as compared with controls. mRNA levels in peripheral blood mononuclear cells (PBMC), evaluated by quantitative RT-PCR analysis, paralleled serum MCP-1 levels. Moreover, a progressive MCP-1 decrease was observed over a 1-year follow up in a subgroup of MCI subjects converted to AD. MCP-1 upregulation is likely to be a very early event in AD pathogenesis, by far preceding the clinical onset of the disease. Nevertheless, as MCP-1 is likely to play a role in several pathologies with an inflammatory component, a possible usfulness as an early AD biomarker would be possible only in combination with other molecules.

AB - Upregulation of a number of chemokines, including monocyte chemotactic protein-1 (MCP-1), is associated with Alzheimer's disease (AD) pathological changes. Emerging evidence suggests that inflammatory events precede the clinical development of AD, as cytokine disregulation has been observed also in patients with mild cognitive impairment (MCI). MCP-1 levels were evaluated in serum samples from 48 subjects with MCI, 94 AD patients and 24 age-matched controls. Significantly increased MCP-1 levels were found in MCI and mild AD, but not in severe AD patients as compared with controls. mRNA levels in peripheral blood mononuclear cells (PBMC), evaluated by quantitative RT-PCR analysis, paralleled serum MCP-1 levels. Moreover, a progressive MCP-1 decrease was observed over a 1-year follow up in a subgroup of MCI subjects converted to AD. MCP-1 upregulation is likely to be a very early event in AD pathogenesis, by far preceding the clinical onset of the disease. Nevertheless, as MCP-1 is likely to play a role in several pathologies with an inflammatory component, a possible usfulness as an early AD biomarker would be possible only in combination with other molecules.

KW - Alzheimer's disease (AD)

KW - Biomarker

KW - Mild cognitive impairment (MCI)

KW - Monocyte chemoattractant protein-1 (MCP-1)

UR - http://www.scopus.com/inward/record.url?scp=33749998363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749998363&partnerID=8YFLogxK

U2 - 10.1016/j.neurobiolaging.2005.10.007

DO - 10.1016/j.neurobiolaging.2005.10.007

M3 - Article

VL - 27

SP - 1763

EP - 1768

JO - Neurobiology of Aging

JF - Neurobiology of Aging

SN - 0197-4580

IS - 12

ER -